SCHEMBL1884340

SCHEMBL1884340

CSc1nccc(CC#N)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.40
KMT2A Q03164 3/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 2/20 0.39
MAPK9 P45984 1/20 0.37
MAPK10 P53779 1/20 0.37
GAA P10253 3/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
FFAR4 Q5NUL3 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
CCNT1 O60563 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12636463 0.77 PARP1 (0.47) PARP1KMT2AMAPTMEN1GAA
SCHEMBL28266404 0.76 PARP1 (0.44) PARP1KMT2AMAPTMEN1MAPK9
SCHEMBL1130670 0.76 PARP1 (0.43) PARP1KMT2AMAPTMEN1MAPK9
SCHEMBL12886408 0.76 LMNA (0.43) PARP1KMT2AMAPTMEN1GAA
SCHEMBL14548249 0.76 PARP1 (0.43) PARP1KMT2AMAPTMEN1MAPK9
SCHEMBL1881628 0.76 PARP1 (0.43) PARP1KMT2AMAPTMEN1GAA
SCHEMBL1725109 0.76 PARP1 (0.43) PARP1KMT2AMAPTMEN1GAA
SCHEMBL28177928 0.76 PARP1 (0.43) PARP1KMT2AMAPTMEN1MAPK9
SCHEMBL25786474 0.76 MEN1 (0.42) KMT2AMAPTMEN1GAAALDH1A1
SCHEMBL9587836 0.74 PARP1 (0.42) PARP1KMT2AMAPTMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49556-E1 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-06-20 US disclosed
US-RE49556-E1 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-06-20 US disclosed
US-20230116233-A1 Compounds And Compositions As Protein Kinase Inhibitors ARRAY BIOPHARMA INC (US) 2023-04-13 US disclosed
US-20200323852-A1 Compounds And Compositions As Protein Kinase Inhibitors IRM LLC (BM) 2020-10-15 US disclosed
US-20200323852-A1 Compounds And Compositions As Protein Kinase Inhibitors IRM LLC (BM) 2020-10-15 US disclosed
US-10576080-B2 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-03-03 US disclosed
US-10576080-B2 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-03-03 US disclosed
US-10568884-B2 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-02-25 US disclosed
US-10568884-B2 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-02-25 US disclosed
US-20180297985-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2018-10-18 US disclosed
CN-102725283-A Compounds and compositions as protein kinase inhibitors IRM LLC 2012-10-10 CN disclosed
EP-2470526-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2012-07-04 EP disclosed
EP-1832584-B1 PYRIMIDINYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-12-21 EP disclosed
US-20110306625-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-12-15 US disclosed
US-20110306625-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-12-15 US disclosed
US-7939536-B2 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent ASKA PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
WO-2011025927-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-03-03 WO disclosed
WO-2011025927-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-03-03 WO disclosed
US-20080114003-A1 Pyrimidinylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-15 US disclosed
EP-1832584-A1 PYRIMIDINYLISOXAZOL DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200323852-A1 Compounds And Compositions As Protein Kinase Inhibitors BRAF, RAF1, ARAF PARP1 1951/4885KMT2A 2400/4885MAPT 1828/4885
US-20110306625-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF PARP1 1951/4885KMT2A 2400/4885MAPT 1828/4885
US-10568884-B2 Compounds and compositions as protein kinase inhibitors BRAF, RAF1, ARAF PARP1 1951/4885KMT2A 2400/4885MAPT 1828/4885
US-20180297985-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF PARP1 1951/4885KMT2A 2400/4885MAPT 1828/4885
US-20230116233-A1 Compounds And Compositions As Protein Kinase Inhibitors BRAF, RAF1, ARAF PARP1 1951/4885KMT2A 2400/4885MAPT 1828/4885
US-20080114003-A1 Pyrimidinylisoxazole Derivatives MAPK3, MAPK7, MAP3K7 PARP1 3102/4885KMT2A 1336/4885MAPT 4185/4885
US-10576080-B2 Compounds and compositions as protein kinase inhibitors BRAF, RAF1, ARAF PARP1 1951/4885KMT2A 2400/4885MAPT 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.